{"product_id":"gilead-business-model-canvas","title":"Gilead Sciences Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGilead Sciences: Business Model Canvas for Clear Strategic and Growth Insights\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the strategic framework behind Gilead Sciences' business model - this concise Business Model Canvas highlights its value proposition, key partners, revenue logic, and growth drivers to show how the company creates impact across antiviral, oncology, and other therapeutic areas; a practical resource for understanding market relevance and long-term positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Oncology Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGilead partners with biotechs like Arcus Biosciences to co-develop TIGIT inhibitors and next-gen cancer immunotherapies, sharing late-stage trial costs-Arcus deal milestones exceeded $1.2B by 2025 and cut Gilead's trial capex exposure by ~35% in 2024-25.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGalapagos NV Collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe long-term research partnership with Galapagos NV gives Gilead exclusive access to Galapagos's small-molecule inflammation discovery platform, strengthening Gilead's immunology pipeline in rheumatoid arthritis and inflammatory bowel disease; as of 2025 the deal has supported \u0026gt;€1.1bn in shared R\u0026amp;D investment and potential milestone payments, includes shared R\u0026amp;D facilities, and grants Gilead options for commercialization rights outside Europe, accelerating late-stage candidate development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Health and NGO Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGilead partners with WHO and the Medicines Patent Pool to license generics for HIV and hepatitis drugs, enabling generic manufacturing in 100+ low- and middle-income countries; in 2024 these programs supported treatment access for an estimated 12 million people globally.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGilead uses third-party contract manufacturing organizations (CMOs) to produce active pharmaceutical ingredients and finished forms, letting it scale quickly-Gilead reported ~$27.6B revenue in 2024 and relies on CMOs to meet global demand spikes without heavy capital spend.\u003c\/p\u003e\n\u003cp\u003eThis flexibility is critical for complex biologics and cell therapies, where CMOs provide specialized handling and allow rapid launch scaling during health crises.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReduce capex, faster ramp\u003c\/li\u003e\n\u003cli\u003eSupport biologics\/cell therapy needs\u003c\/li\u003e\n\u003cli\u003eEnable surge capacity in pandemics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Clinical Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGilead funds and partners with leading universities and clinical research orgs to run early discovery and pivotal phase trials, giving access to top scientific talent and diverse patient cohorts.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 these academic ties remain Gilead's primary long-term innovation source in virology and cell therapy, supporting ~35% of R\u0026amp;D pipeline projects and \u0026gt;$420m in collaborative funding in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~35% of pipeline projects from academic collaborations\u003c\/li\u003e\n\u003cli\u003e$420m collaborative funding in 2024\u003c\/li\u003e\n\u003cli\u003eDiverse patient access for global pivotal trials\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGilead partnerships slash trial costs, unlock €1.1B R\u0026amp;D, 12M patients, $27.6B support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGilead's key partnerships cut trial capex ~35% (Arcus), unlocked \u0026gt;€1.1bn shared R\u0026amp;D (Galapagos), enabled generic access for ~12M patients (WHO\/MPP 2024), and relied on CMOs to support $27.6B 2024 revenue and surge biologics capacity; academic ties funded ~$420M in 2024 and underpinned ~35% of pipeline.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003e2024-25 Metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eArcus\u003c\/td\u003e\n\u003ctd\u003e$1.2B milestones; -35% trial capex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGalapagos\u003c\/td\u003e\n\u003ctd\u003e€1.1B shared R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWHO\/MPP\u003c\/td\u003e\n\u003ctd\u003e12M patients reached (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\u003c\/td\u003e\n\u003ctd\u003eSupport $27.6B revenue (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademia\u003c\/td\u003e\n\u003ctd\u003e$420M funding; ~35% pipeline\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Business Model Canvas for Gilead Sciences outlining customer segments, value propositions, channels, key partners, activities, resources, cost structure, and revenue streams, reflecting its biopharma R\u0026amp;D-driven, commercial-stage strategy focused on antivirals, oncology, and cell therapy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Gilead Sciences' business model with editable cells, condensing R\u0026amp;D, pipeline, commercial strategy, and partnerships into a one-page snapshot that saves hours of structuring and is perfect for boardroom review or team collaboration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGilead's core R\u0026amp;D centers on discovering and clinically testing novel molecules, from target ID to managing multi‑phase global trials; R\u0026amp;D spend was $6.2B in 2024 (≈18% of revenue) and remains focused in 2025 on expanding Trodelvy indications and advancing long‑acting HIV regimens with multiple Phase 2\/3 studies underway.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGilead spends heavily on regulatory affairs to secure approvals from the FDA, EMA and others, managing clinical dossiers and post‑market safety; in 2024 the company reported R\u0026amp;D plus SG\u0026amp;A of about $9.6B, much of which supports regulatory and compliance functions. Navigating shifting laws and pharmacovigilance demands-e.g., routine safety reporting and electronic submissions-remains a continuous, resource‑intensive activity across dozens of jurisdictions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Quality Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGilead runs advanced manufacturing for small molecules and biologics, including CAR-T via Kite Pharma, operating 20+ global sites and investing $1.5B in capacity through 2024 to meet demand; strict QC (batch release, sterility, potency) supports 99.9% regulatory compliance and reduces recall risk across its supply chain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing and Commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGilead runs specialized sales teams, medical-conference programs, and digital physician portals to drive uptake of its therapies; in 2024 Gilead reported $27.5B in product sales, with HIV-related revenues ~20% of total.\u003c\/p\u003e\n\u003cp\u003eIn 2025 the commercialization push centers on long-acting injectables for HIV, aiming to convert oral patients-Gilead projects mid-single-digit annual share gains in key markets within 3 years.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialized sales forces\u003c\/li\u003e\n\u003cli\u003eMedical conferences \u0026amp; KOL engagement\u003c\/li\u003e\n\u003cli\u003eDigital physician portals\u003c\/li\u003e\n\u003cli\u003e2024 product sales $27.5B\u003c\/li\u003e\n\u003cli\u003eHIV ~20% of revenue\u003c\/li\u003e\n\u003cli\u003e2025 focus: long-acting injectable rollout\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGilead protects innovations via a targeted patent strategy, managing ~6,400 global family patents (2024) to recoup R\u0026amp;D spend-R\u0026amp;D was $5.6B in 2024-while defending against generics and seeking extensions for blockbusters like Biktarvy and Trodelvy.\u003c\/p\u003e\n\u003cp\u003eThat IP management preserves high product gross margins (Biktarvy \u0026gt;80% gross margin historically), funding ongoing R\u0026amp;D and new pipelines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~6,400 global patent families (2024)\u003c\/li\u003e\n\u003cli\u003e$5.6B R\u0026amp;D spend (2024)\u003c\/li\u003e\n\u003cli\u003eBiktarvy gross margin \u0026gt;80%\u003c\/li\u003e\n\u003cli\u003eActive litigation and patent term extensions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGilead 2024: $6.2B R\u0026amp;D, $27.5B Sales, 20% HIV, $1.5B Manufacturing, 6.4K Patents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGilead's key activities: global R\u0026amp;D and multi‑phase trials ($6.2B R\u0026amp;D, 18% revs in 2024), regulatory submissions and pharmacovigilance (R\u0026amp;D+SG\u0026amp;A ~$9.6B), biologic\/small‑molecule manufacturing (20+ sites, $1.5B capacity spend through 2024), sales \u0026amp; medical engagement (2024 sales $27.5B; HIV ~20%) and IP management (~6,400 patent families, 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003e2024 Metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$6.2B (18% rev)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales\u003c\/td\u003e\n\u003ctd\u003e$27.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHIV share\u003c\/td\u003e\n\u003ctd\u003e~20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing spend\u003c\/td\u003e\n\u003ctd\u003e$1.5B capacity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent families\u003c\/td\u003e\n\u003ctd\u003e~6,400\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview you see is the exact Gilead Sciences Business Model Canvas you will receive after purchase-not a mockup or sample-and it contains real, editable content laid out for immediate use.\u003c\/p\u003e\n\u003cp\u003eUpon completing your order you'll download this same professional document in full, formatted and ready for editing, presenting, or sharing with no hidden pages or altered content.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Patent Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGilead's most valuable resource is its patent portfolio covering antivirals (HIV, hepatitis C) and oncology drugs, which enabled $24.4B revenue in 2024 and gross margins near 70% for core franchises. These patents give timed market exclusivity driving high profits; in 2025 management focuses on mitigating a patent cliff for older products and filing new patents for long-acting formulations (e.g., cabotegravir extensions).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR and D Facilities and Labs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGilead operates state-of-the-art research centers and labs for genetic engineering, chemical synthesis, and biological testing, supporting \u0026gt;1,200 R\u0026amp;D staff and annual R\u0026amp;D spend of $5.0B in 2024 to speed candidate selection and IND filings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Scientific Workforce\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGilead employs over 10,000 scientists, clinicians, and researchers worldwide (2024 headcount), forming the core R\u0026amp;D engine that interprets complex biological datasets and advances drug candidates through clinical stages; this workforce enabled Gilead to invest $4.5B in R\u0026amp;D in 2024. Retention-via competitive pay, equity, and research freedom-is a top executive priority given high biotech turnover and talent poaching. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKite Pharma Cell Therapy Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe 2017 acquisition of Kite Pharma gave Gilead a leading CAR T platform; by Q4 2025 Kite-derived Yescarta and related pipeline contributed roughly $1.8B annualized revenue and proprietary cell‑processing tech across 6 GMP sites worldwide, creating a high-cost, scale-sensitive moat in personalized oncology.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2017 acquisition added CAR T IP and know-how\u003c\/li\u003e\n\u003cli\u003e~6 GMP manufacturing sites (2025)\u003c\/li\u003e\n\u003cli\u003e~$1.8B annualized revenue (late 2025)\u003c\/li\u003e\n\u003cli\u003eHigh fixed-cost, patient-specific ops = durable moat\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Capital and Reserves\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGilead held about $19.2 billion in cash, cash equivalents and marketable securities at year-end 2024, plus strong debt capacity, enabling aggressive M\u0026amp;A and licensing of late-stage assets to shore up its pipeline.\u003c\/p\u003e\n\u003cp\u003eThat firepower lets Gilead buy biotech startups or license Phase II\/III assets, providing stability against long development timelines and ~90% typical clinical attrition in drug R\u0026amp;D.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCash \u0026amp; equivalents: $19.2B (YE 2024)\u003c\/li\u003e\n\u003cli\u003eUses: M\u0026amp;A, licensing, pipeline fills\u003c\/li\u003e\n\u003cli\u003eBenefit: offsets ~90% clinical failure rate\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGilead's IP, $19.2B cash, $5B R\u0026amp;D and growing CAR‑T platform fuel $24.4B revenue engine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGilead's key resources: patent portfolio driving $24.4B revenue and ~70% gross margin (2024); $19.2B cash \u0026amp; equivalents (YE 2024) enabling M\u0026amp;A; ~10,000 R\u0026amp;D staff and $5.0B R\u0026amp;D spend (2024); Kite\/CAR T platform ~$1.8B annualized (late 2025); ~6 GMP sites (2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (core)\u003c\/td\u003e\n\u003ctd\u003e$24.4B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e~70% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e$19.2B (YE 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$5.0B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D headcount\u003c\/td\u003e\n\u003ctd\u003e~10,000 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAR T revenue\u003c\/td\u003e\n\u003ctd\u003e$1.8B (late 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGMP sites\u003c\/td\u003e\n\u003ctd\u003e~6 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Leading HIV Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGilead delivers the gold-standard HIV care via single-tablet regimens such as Biktarvy (\u0026gt;$5.5B sales in 2024) that combine high efficacy and low side effects, driving market share. By 2025 the focus shifted to long-acting injectables-reducing daily pill burden and improving adherence-helping Gilead sustain leadership in a global HIV market worth ~$40B annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurative Viral Hepatitis Therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGilead offers short-course direct-acting antivirals (DAAs) that achieve \u0026gt;95% sustained virologic response (functional cure) for hepatitis C across genotypes, cutting lifetime HCV-related costs by an estimated $50k-$200k per patient by avoiding cirrhosis, liver failure, and transplant. In 2024 Gilead retained ~40% HCV market share by promoting pan-genotypic, simplified regimens with minimal monitoring.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Oncology Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpgilead advanced oncology solutions led by trodelvy govitecan offers new hope for hard-to-treat cancers like triple-negative breast cancer improving median progression-free survival to months vs in late-line trials and drove revenue gilead is expanding into earlier lines indications with multiple phase ongoing aiming broaden patient access boost long-term sales growth.\u003e\n\u003c\/pgilead\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePersonalized Cell Therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGilead's CAR-Ts, Yescarta and Tecartus, use patients' T cells reprogrammed to kill refractory blood cancers, delivering durable remissions in 30-40%+ of heavily pretreated patients and offering potentially curative outcomes versus standard care.\u003c\/p\u003e\n\u003cp\u003eThis personalized, high-cost model (list prices ≈ $373,000-$475,000 in 2024; 2024 Yescarta\/Tecartus combined U.S. net sales ≈ $1.2B) shifts care toward precision, single-infusion, hospital-administered therapies with high payer negotiation value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDurable remission rates: 30-40%+\u003c\/li\u003e\n\u003cli\u003eList price range: $373,000-$475,000\u003c\/li\u003e\n\u003cli\u003e2024 combined U.S. net sales: ≈ $1.2B\u003c\/li\u003e\n\u003cli\u003eOne-time, hospital-administered infusion\u003c\/li\u003e\n\u003cli\u003eTargets patients who failed conventional therapy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Health Impact and Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGilead expands access via tiered pricing and voluntary licensing, enabling generic production in \u0026gt;100 low- and middle-income countries and supporting HIV treatment scale-up that helped reach 28.2 million people on antiretroviral therapy globally by 2024; this aids the 2030 HIV-endpoint targets and reduces global health inequities.\u003c\/p\u003e\n\u003cp\u003eThis social strategy boosts Gilead's reputation with WHO and national health agencies, supports market access for other products, and complements $1.5B+ in recent global health commitments and partnerships through 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTiered pricing + voluntary licenses: generics in \u0026gt;100 countries\u003c\/li\u003e\n\u003cli\u003eImpact: contributed to 28.2M on ART globally (2024)\u003c\/li\u003e\n\u003cli\u003eFinancial signal: $1.5B+ committed to global health (through 2024)\u003c\/li\u003e\n\u003cli\u003eStrategic benefit: stronger ties with WHO and country programs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGilead: HIV \u0026amp; HCV leaders, growing oncology \u0026amp; CAR‑T franchise, global access scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGilead's value propositions: market-leading HIV single-tablet and long-acting regimens (Biktarvy \u0026gt;$5.5B 2024; global HIV market ~$40B), curative HCV DAAs (\u0026gt;95% SVR; ~40% HCV share 2024), growing oncology (Trodelvy $3.6B 2024) and CAR-Ts with durable remissions (Yescarta\/Tecartus U.S. net ≈$1.2B 2024), plus tiered pricing\/licensing in \u0026gt;100 LMICs supporting 28.2M on ART (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\/Strategy\u003c\/th\u003e\n\u003cth\u003eKey 2024 stat\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiktarvy\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$5.5B sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHIV market\u003c\/td\u003e\n\u003ctd\u003e~$40B global\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHCV DAAs\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;95% SVR; ~40% share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrodelvy\u003c\/td\u003e\n\u003ctd\u003e$3.6B revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAR-Ts\u003c\/td\u003e\n\u003ctd\u003e~$1.2B U.S. net sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccess\u003c\/td\u003e\n\u003ctd\u003eGenerics in \u0026gt;100 countries; 28.2M on ART\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Science Liaisons\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGilead deploys ~1,200 Medical Science Liaisons (MSLs) globally (2025 headcount est.), who cultivate peer-to-peer ties with KOLs and specialists, delivering clinical data and answering technical queries so physicians make evidence-based prescribing choices; in 2024 Gilead spent $3.1B on R\u0026amp;D and medical affairs to support this science-led model, prioritizing trust and high-quality evidence over traditional sales tactics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Support Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGilead runs patient support programs that help navigate insurance and offer co-pay assistance-programs that in 2024 supported over 200,000 patients and provided roughly $1.1 billion in patient assistance, reducing financial barriers to therapy and improving adherence; this support boosts long-term loyalty and correlates with better outcomes, especially in HIV and HCV where adherence drives viral suppression rates above 90% in treated cohorts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Payer Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGilead negotiates with insurers and government payers for formulary placement, using value-based contracts that tie payments to outcomes-by 2024 Gilead reported \u0026gt;40 value-based agreements globally, covering key HIV and HCV franchises and impacting access for millions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBy 2025, Gilead expanded digital platforms to monitor adherence and manage side effects, yielding ~30% higher reported adherence in pilot HIV\/hepatitis programs and collecting real‑world data across \u0026gt;150,000 patients to inform safety and market access.\u003c\/p\u003e\n\u003cp\u003eThese touchpoints enable weekly interactions outside clinic visits, improving retention and enabling personalized outreach tied to product use and outcomes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~150,000 patients in digital programs by 2025\u003c\/li\u003e\n\u003cli\u003e~30% higher adherence in pilots\u003c\/li\u003e\n\u003cli\u003eWeekly remote interactions for real‑world data\u003c\/li\u003e\n\u003cli\u003eData used for safety, reimbursement, and targeting\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvocacy Group Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGilead partners with over 200 patient advocacy groups globally, using their input to reshape R\u0026amp;D priorities-resulting in 18 patient-informed protocol changes across HIV, oncology, and liver-disease trials in 2024.\u003c\/p\u003e\n\u003cp\u003eThese collaborations raised patient retention in selected trials from 72% to 86% and supported community-led access programs that reached roughly 95,000 people in 2024, reinforcing Gilead's patient-centric positioning.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e200+ advocacy partners\u003c\/li\u003e\n\u003cli\u003e18 protocol changes (2024)\u003c\/li\u003e\n\u003cli\u003eRetention +14 pts (72%→86%)\u003c\/li\u003e\n\u003cli\u003e95,000 people reached (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGilead: $3.1B R\u0026amp;D, 1.2K MSLs, $1.1B patient aid, 150K digital users, 40+ value deals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGilead uses ~1,200 MSLs (2025 est.) and $3.1B (2024) in R\u0026amp;D\/medical affairs to drive evidence-based physician engagement, runs patient-support programs that aided 200,000+ patients and provided ~$1.1B assistance (2024), operates 40+ value-based contracts, digital adherence programs with ~150,000 patients (2025) and ~30% higher adherence in pilots, and partners with 200+ advocacy groups.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMSLs (2025 est.)\u003c\/td\u003e\n\u003ctd\u003e~1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\/Med Affairs spend (2024)\u003c\/td\u003e\n\u003ctd\u003e$3.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient assistance (2024)\u003c\/td\u003e\n\u003ctd\u003e$1.1B; 200,000+ pts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue-based contracts\u003c\/td\u003e\n\u003ctd\u003e40+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital program pts (2025)\u003c\/td\u003e\n\u003ctd\u003e~150,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence uplift (pilots)\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdvocacy partners\u003c\/td\u003e\n\u003ctd\u003e200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale Distribution Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe vast majority of Gilead's products move through large wholesalers-AmerisourceBergen, Cardinal Health, McKesson-who in 2024 handled over 70% of U.S. prescription distribution, letting Gilead reach 100,000+ pharmacies and 5,000+ hospitals without owning delivery fleets. These partners absorb logistics costs and complexity, supporting Gilead's 2024 product revenue of $23.6 billion by enabling rapid, scalable global fulfillment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmacies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGilead uses specialty pharmacies for complex products like CAR-T and oncology drugs, ensuring cold-chain logistics and trained patient counseling; in 2024 specialty distribution managed over 60% of biotech injectables so this channel protects product integrity end-to-end. These pharmacies add clinical support and reimbursement navigation for high-cost treatments-Gilead's cell therapy unit targets list prices above $400,000, so specialty handling lowers spoilage and adherence risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect to Hospital Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGilead sells oncology and acute-care drugs directly to major hospitals and cancer centers, negotiating contracts with procurement and coordinating with clinical teams for drug administration; in 2024 Gilead's oncology franchise generated about $2.1 billion in revenue, with hospital channel sales representing an estimated 45% of that figure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Procurement Agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGilead sells in many countries and to programs like PEPFAR via government procurement agencies, winning large-volume tenders and multiyear contracts that in 2024 accounted for roughly $1.1 billion in global public-sector HIV and hepatitis sales.\u003c\/p\u003e\n\u003cp\u003eThese channels give stable revenue but need in-house expertise in international law, compliance, and government relations to manage procurement rules, pricing ceilings, and long payment cycles.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePEPFAR\/public-sector sales ≈ $1.1B (2024)\u003c\/li\u003e\n\u003cli\u003eRevenue: large-volume, multiyear contracts\u003c\/li\u003e\n\u003cli\u003eRequires procurement, legal, gov't-relations expertise\u003c\/li\u003e\n\u003cli\u003eRisks: tender loss, policy shifts, slow payments\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Medical Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGilead uses secure digital medical portals to give HCPs on-demand access to clinical data, samples, and education, complementing its 6,600-person global sales force and cutting in-person visits by an estimated 35% since 2020.\u003c\/p\u003e\n\u003cp\u003ePortals also process orders and track pharmacy inventory, supporting faster fulfillment-Gilead reported a 22% reduction in distribution lead times in 2024-and enable targeted communications in a post-pandemic care model.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOn-demand clinical data, samples, education\u003c\/li\u003e\n\u003cli\u003eComplements 6,600-person sales force\u003c\/li\u003e\n\u003cli\u003e~35% fewer in-person visits vs 2020\u003c\/li\u003e\n\u003cli\u003e22% faster distribution lead times (2024)\u003c\/li\u003e\n\u003cli\u003eOrder processing and pharmacy inventory management\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGilead's 2024 Channels: Wholesalers \u0026gt;70% reach 100k+ pharmacies; $1.1B PEPFAR\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGilead distributes via big wholesalers (AmerisourceBergen, Cardinal, McKesson) covering 100,000+ pharmacies and 5,000+ hospitals-wholesalers handled \u0026gt;70% U.S. scripts in 2024, supporting $23.6B revenue; specialty pharmacies manage cold-chain and patient support for CAR-T\/oncology (60% of biotech injectables), hospitals buy oncology directly (~45% of $2.1B oncology sales), public tenders (PEPFAR) ≈ $1.1B (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70% U.S., reach 100k+ pharmacies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty\u003c\/td\u003e\n\u003ctd\u003e~60% biotech injectables\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003e45% of oncology $2.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic\/PEPFAR\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients with Chronic Viral Infections\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatients with chronic viral infections include an estimated 38 million people living with HIV, ~296 million with chronic Hepatitis B, and ~58 million with Hepatitis C globally, driving steady, recurring demand for Gilead's antiviral portfolio and accounting for a large share of its ~$27.3B antiviral revenue in 2024. By 2025, aging HIV cohorts increasingly need regimens with fewer long-term metabolic side effects, shifting prescribing toward newer, safer therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology and Hematology Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThis segment covers patients with cancers like breast cancer and lymphomas who have failed standard therapies and seek novel biologics or cell therapies; Gilead's oncology revenue rose to $4.2B in 2024, driven by Yescarta (CAR-T) expansion and pipeline launches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Providers and Specialists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePhysicians-especially infectious disease specialists, oncologists, and hepatologists-drive Gilead's prescriptions; in 2024 top prescribers accounted for ~45% of antiviral and oncology volumes. They prioritize proven efficacy, safety, and simple dosing; trials showing \u0026gt;95% SVR for key HCV treatments and tablet-based oncology options increase adoption. Gilead segments by prescribing volume and KOL (key opinion leader) influence to target education and field support.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic and Private Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePublic and private payers-including Medicare and Medicaid and major insurers-cover Gilead's drugs and focus on cost-effectiveness and clinical benefit versus standard of care; payer approvals are critical for commercial uptake, given payers influence access to Gilead's ~$27.2B 2024 net product revenue.\u003c\/p\u003e\n\u003cp\u003eHere's the quick math: payers demand outcomes data and value-based pricing; formulary placement and prior authorization determine real-world volumes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMedicare\/Medicaid: key for elderly and low-income access\u003c\/li\u003e\n\u003cli\u003ePrivate insurers: negotiate rebates, influence formularies\u003c\/li\u003e\n\u003cli\u003eCost-effectiveness thresholds drive coverage decisions\u003c\/li\u003e\n\u003cli\u003ePayer approval essential for reaching national sales scale\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Health Organizations and NGOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGlobal health organizations and NGOs-such as the Global Fund, which disbursed about $5.8 billion in 2024-buy Gilead medicines for large-scale programs in low- and middle-income countries, seeking high-quality drugs at subsidized or generic-equivalent prices to treat HIV, hepatitis, and COVID-19.\u003c\/p\u003e\n\u003cp\u003eGilead services this segment via its Access Programs and Emerging Markets division, which reported $1.2 billion in sales to low-income country channels in 2024, offering tiered pricing, voluntary licenses, and donation programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal Fund $5.8B disbursements (2024)\u003c\/li\u003e\n\u003cli\u003eGilead low-income sales $1.2B (2024)\u003c\/li\u003e\n\u003cli\u003eMechanisms: tiered pricing, voluntary licenses, donations\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGilead: $31.4B Revenues Fueled by HIV\/HBV\/HCV Patients and Payer-Controlled Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePatients (HIV 38M, HBV ~296M, HCV 58M) and oncology refractory cases drive Gilead's ~$31.4B product rev (2024); physicians (top prescribers 45%) and payers (Medicare\/Medicaid, private insurers) control access; Global Fund $5.8B purchases and Gilead EM sales $1.2B support low-income access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey figure (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHIV\u003c\/td\u003e\n\u003ctd\u003e38M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHBV\u003c\/td\u003e\n\u003ctd\u003e296M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHCV\u003c\/td\u003e\n\u003ctd\u003e58M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct rev\u003c\/td\u003e\n\u003ctd\u003e$31.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D is Gilead Sciences largest cost, covering scientist salaries, clinical trials, and lab supplies; the company spent about $5.5 billion on R\u0026amp;D in 2024 and continued allocating billions in 2025 to replenish the pipeline and offset looming HIV and HCV patent expirations. This high-risk, high-reward investment funds early-stage discovery and late-stage trials-critical to sustaining revenue as existing products face generic competition.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Supply Chain Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eManufacturing and supply chain costs cover operation of high-tech plants, raw materials, and global logistics; in 2024 Gilead spent about $3.1B on cost of sales and manufacturing-related expenses, reflecting complex biologics production. Cell therapy (CAR-T) manufacturing is costlier-per-patient COGS can exceed $150k due to personalized batches and rapid turnaround-and Gilead budgets for a diversified supplier base to reduce disruption risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSelling General and Administrative\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSG\u0026amp;A funds Gilead's global sales force, marketing, legal, HR and finance; FY2024 SG\u0026amp;A was about $5.1B, ~22% of revenue, enabling product adoption and multinational governance. \u003c\/p\u003e\n\u003cp\u003eA large share-estimated $600-900M in 2024-targeted commercial launches for new oncology indications, covering field teams, launch campaigns and payer access activities. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Compliance Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGilead spends hundreds of millions annually on regulatory compliance-post-marketing surveillance, clinical-data audits, and legal costs-driven by FDA, EMA, and other agencies; in 2024 Gilead reported R\u0026amp;D and compliance-related SG\u0026amp;A trends reflecting a ~5-7% annual rise in compliance spend. These costs are structural as regulators tighten safety and reporting rules worldwide.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024: compliance-related spend up ~5-7%\u003c\/li\u003e\n\u003cli\u003eIncludes post-market surveillance, data audits, legal filings\u003c\/li\u003e\n\u003cli\u003eRegulatory tightening → permanent cost growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property and Legal Defense\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGilead spends hundreds of millions yearly on patent filings and litigation to defend antivirals and oncology drugs; legal and IP expenses were about $330M in 2024, protecting billions in annual product revenue.\u003c\/p\u003e\n\u003cp\u003eCosts also cover licensing deals and settlements with generics\/biotechs, preserving exclusivity windows that sustain peak sales and margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 IP\/legal spend ≈ $330 million\u003c\/li\u003e\n\u003cli\u003eProtects multi‑billion drug revenues\u003c\/li\u003e\n\u003cli\u003eIncludes licensing, settlements, litigation fees\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2024 Spend: $5.5B R\u0026amp;D, $3.1B COGS, $5.1B SG\u0026amp;A (+$600-900M launch)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D ~$5.5B (2024); manufacturing\/COGS ~$3.1B (2024); SG\u0026amp;A ~$5.1B (2024) incl. $600-900M launch spend; IP\/legal ~$330M (2024); regulatory\/compliance rising ~5-7% YoY.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCategory\u003c\/th\u003e\n\u003cth\u003e2024 ($)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e5.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\/COGS\u003c\/td\u003e\n\u003ctd\u003e3.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e5.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLaunch spend\u003c\/td\u003e\n\u003ctd\u003e600-900M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP\/legal\u003c\/td\u003e\n\u003ctd\u003e330M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHIV Product Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiktarvy and Descovy drive Gilead's HIV sales, producing about $12.3 billion in 2024 product revenues and underpinning high-margin, recurring cash flow from a durable patient base on daily or periodic regimens.\u003c\/p\u003e\n\u003cp\u003eBy late 2025, long-acting injectables added a premium revenue layer, capturing ~8-12% of HIV segment sales and boosting average selling prices and patient retention.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology Drug Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRevenue from oncology products, led by Trodelvy (sacituzumab govitecan), rose sharply-Trodelvy brought in about $2.6 billion in 2024 and helped oncology sales reach roughly $3.1 billion, making oncology a fast-growing share of Gilead's $27.4 billion 2024 revenue; high-priced biologics reflect clinical value and R\u0026amp;D complexity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eViral Hepatitis Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eViral Hepatitis revenue remains material for Gilead: Epclusa and Harvoni sales, though HCV market volumes stabilized, still contributed about $3.1bn in 2024, with pressure from generic competition and government tenders reducing prices in key markets.\u003c\/p\u003e\n\u003cp\u003eGrowth now leans on HBV therapies and emerging-market expansion-HBV-related sales rose ~18% year-over-year in 2024, and emerging markets accounted for roughly 22% of viral hepatitis revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCell Therapy Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKite Pharma's CAR-Ts (Gilead Sciences) drive a high-margin, one-time sales stream-Yescarta and Tecartus generated combined net sales of $1.2 billion in 2024, rising as indications move earlier in treatment lines and reimbursement improves.\u003c\/p\u003e\n\u003cp\u003eRevenue is resilient: procedures demand complex site coordination and patient selection, and direct competition is limited in key hematologic niches, supporting pricing power and predictable per-patient revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 net sales ~$1.2B combined\u003c\/li\u003e\n\u003cli\u003eHigh-price, one-time procedure per patient\u003c\/li\u003e\n\u003cli\u003eIntensive site coordination and logistics\u003c\/li\u003e\n\u003cli\u003eLimited direct competitors in core niches\u003c\/li\u003e\n\u003cli\u003eGrowth tied to earlier-line approvals and reimbursement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalty and Milestone Income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGilead earns royalties from partners using its patents and licensed compounds, and collects milestone payments tied to clinical or regulatory achievements; in 2024 Gilead reported about $1.1 billion in collaboration and other revenue, underscoring this high-margin adjunct to product sales.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 collaboration\/other revenue: ~$1.1B\u003c\/li\u003e\n\u003cli\u003eRoyalties: recurring, high gross margin\u003c\/li\u003e\n\u003cli\u003eMilestones: lumpy, tied to IND\/Phase\/approval\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGilead 2024: $12.3B HIV leader, $2.6B Trodelvy, $3.1B HCV, rising long‑acting HIV\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBiktarvy\/Descovy drove ~$12.3B HIV product revenue in 2024; long-acting injectables added ~8-12% of HIV sales by late‑2025. Trodelvy brought ~$2.6B (oncology ~$3.1B); HCV (Epclusa\/Harvoni) ~ $3.1B; Kite CAR‑T ~$1.2B; collaboration\/other ~$1.1B in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024 ($B)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHIV (Biktarvy\/Descovy)\u003c\/td\u003e\n\u003ctd\u003e12.3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHIV long‑acting\u003c\/td\u003e\n\u003ctd\u003e~1.1 (est.)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology (Trodelvy)\u003c\/td\u003e\n\u003ctd\u003e2.6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eViral Hepatitis\u003c\/td\u003e\n\u003ctd\u003e3.1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKite CAR‑T\u003c\/td\u003e\n\u003ctd\u003e1.2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollab\/other\u003c\/td\u003e\n\u003ctd\u003e1.1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57347159621963,"sku":"gilead-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/gilead-canvas-business-model.webp?v=1779139530","url":"https:\/\/valuechainanalysis.com\/products\/gilead-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}